[ad_1]
TheThe two most important messages have been launched: the acquisition of Spark Therapeutics (ONCE) by Roche (RHHBY), worth $ 5 billion, means that large pharmaceutical companies are embarking on a veritable buying frenzy and that gene therapy, a long-awaited approach to the treatment of hereditary diseases, has come of age.
The Wall Street Journal reported Saturday that Roche was in talks to buy Spark at 150% market capitalization bonus of the smaller company Friday. This morning, the two companies announced that Roche would buy Spark for $ 4.8 billion, or $ 114.50 per share. There are five things to keep in mind about this news for all those who are interested in the biotechnology sector.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!
TO START
What is it?
STAT Plus is a premium subscription that offers scalable biopharmaceutical market coverage and in-depth scientific reports from a team with several decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and first examination of advanced laboratories and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Monthly live subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link